EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

TrxR Inhibition and Nrf2–FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance

Charan Singh Pawar, Nagarajan Rajendra Prasad iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70358 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, 2026. Verfasst von Charan Singh Pawar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biotechnology, Annamalai University, Chidambaram, Tamil Nadu, India. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Drug Resistance, Neoplasm, Thioredoxin-Disulfide Reductase, Antineoplastic Agents. Die Arbeit nennt 179 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A common cause of multidrug‐resistant (MDR) cancer is imbalanced redox signaling, which reduces the effectiveness of chemotherapy and promotes regrowth of cancer cells. Amplification of thioredoxin reductase (TrxR) and activation of the Keap1–Nrf2–FOXO3 pathway may contribute to enhanced drug efflux, strengthens antioxidant defenses, and resistance to oxidative stress‐induced apoptosis in certain tumors. Redox‐based drug repurposing offers a promising strategy to overcome MDR by targeting these shortcomings. Repurposing drugs including metformin, auranofin, brusatol, and natural polyphenols increase reactive oxygen species (ROS) and make MDR cells more sensitive to chemotherapy via modulation and inhibiting Nrf2 or TrxR. Nanotechnology advancements and combination of repurposed drugs with anticancer drugs, ferroptosis inducers may improve tumor selectivity while lowering systemic toxicity. Preclinical experiments show effectiveness by suppressing antioxidant pathways, inhibiting efflux pump function, and delivering drugs in a redox‐responsive manner. Next‐generation tumor‐selective delivery systems, adaptive clinical trial designs, and biomarker‐driven patient classification based on TrxR expression or Keap1/Nrf2 mutations are the main areas of focus. Translation into clinical practice could be accelerated by combining specific redox profiling, nanocarrier technologies, and pharmacokinetics. For MDR cancer, redox‐targeted drug repurposing is an effective, precision‐based strategy for recovering chemosensitivity and enhancing treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2Drug Resistance, NeoplasmThioredoxin-Disulfide ReductaseAntineoplastic AgentsForkhead Box Protein O3NeoplasmsHumansDrug RepositioningDrug Resistance, MultipleAnimalsOxidation-ReductionKelch-Like ECH-Associated Protein 1

Stichwörter der Autor:innen

Keap1–Nrf2–FOXO3 signaling pathwayROSauranofinmultidrug resistancerepurposed drugsthioredoxin reductase

Substanzen

NF-E2-Related Factor 2Thioredoxin-Disulfide ReductaseAntineoplastic AgentsForkhead Box Protein O3NFE2L2 protein, humanFOXO3 protein, humanKelch-Like ECH-Associated Protein 1

Autor:innen und Institutionen

  • Department of Biochemistry and Biotechnology, Annamalai University, Chidambaram, Tamil Nadu, India.

ORCID-Profile: Nagarajan Rajendra Prasad

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Pawar, C. S., & Prasad, N. R. (2026). TrxR Inhibition and Nrf2–FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance. Drug Development Research. https://doi.org/10.1002/ddr.70358

Vancouver

Pawar CS, Prasad NR. TrxR Inhibition and Nrf2–FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance. Drug Development Research. 2026. doi:10.1002/ddr.70358

BibTeX
@article{Pawar2026,
  author = {Pawar, Charan Singh and Prasad, Nagarajan Rajendra},
  title = {TrxR Inhibition and Nrf2–FOXO3 Modulation by Repurposed Drugs: A Redox Strategy to Reverse Cancer Multidrug Resistance},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70358}
}
Kostenlos starten →